The biotech engaged with the FDA on alternative pathways to approval after seeing safety and efficacy data from the phase 1/2 ...

Editas Medicines has signed a $238 million biobucks pact to combine Genevant Science’s lipid nanoparticle (LNP) tech with the ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...

The FDA has granted a de novo clearance to a new type of stent designed to hold open the passages down the windpipe and into ...

China-based Minghui Pharmaceutical has linked its thyroid eye disease treatment to a reduction in eye bulging in a small ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

Horizon Surgical Systems, a startup developing automated, artificial intelligence-powered robotic tools for eye surgery, has ...

Boston Scientific collected a set of FDA green lights for an update to its pulsed field ablation system for atrial ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Italy’s Angelini Pharma has signed a $360 million biobucks pact centered on a phase 1-stage brain health drug from South ...